Please assess the completion status of the following clinical trial:

Trial Title: Compassionate Use of an Intravenous Fish Oil Emulsion in the Treatment of Liver Injury in Infants

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Be greater than 14 days old and less than 5 years old~* Conjugated bilirubin greater than 2 mg/dL.~* Be expected to require intravenous nutrition for at least an additional 28 days~Exclusion Criteria:~* Have a congenitally lethal condition (e.g. Trisomy 13).~* Have clinically severe bleeding not able to be managed with routine measures.~* Have evidence of a viral hepatitis or primary liver disease as the primary etiology of their cholestasis.~* Have other health problems such that survival is extremely unlikely even if the infant's cholestasis improves.~Home Use of Omegaven®:~In order for a subject to receive the Omegaven® at home through a home health care agency, subjects will first be required to be admitted to Texas Children's Hospital for 72 hours in initiate the administration of the Omegaven®. This will allow time for observation of any unexpected side effects and for parents to be provided education on home TPN and Omegaven®.~If a subject has already received Omegaven® either at TCH or at another hospital, they will not be required to be admitted for the 72 hour inpatient admission prior to starting Omegaven® at home. Parent training will occur during the previous hospital admission and will continue through the TCH Pediatric Intestinal Rehabilitation Clinic.~Outpatient Monitoring:~After the initial evaluation by the TCH Pediatric Intestinal Rehabilitation Clinic physicians, subjects will return to the clinic for routine follow-up. Subjects will be asked to return to the clinic every 2 weeks for the first 2 months of treatment. Thereafter, subjects will return to the clinic on a monthly basis, or as directed by the clinic team.

- Gender: ALL
- Minimum Age: 14 Days
- Maximum Age: 5 Years
- Healthy Volunteers: f

Study Arms:
- Fish Oil Emulsion Arm (Type: EXPERIMENTAL): In infants who meet the eligibility criteria for Fish Oil Emulsion arm will receive Fish Oil Emulsion after enrollment under the study.~Therapy with Fish Oil Emulsion (Omegaven) will be provided at a dose of 1 gm/kg/day (by continuous infusion) and will be infused intravenously through either a central or peripheral catheter in conjunction with parenteral nutrition. If previously on Intralipid, it will be stopped prior to initiation of Fish Oil Emulsion.Fish oil emulsion will be provided as a continuous intravenous emulsion over 24 hours.

Based on this trial design, predict the completion outcome and termination type (if applicable).